Metabolic dysfunction-associated fatty liver disease and liver fibrosis score in patients with COVID-19 as predictors of adverse clinical outcomes: an artificial intelligent application through machine learning

Abstract

Introduction and aims. Patients with coronavirus disease-2019 (COVID-19) and metabolic-dysfunction associated fatty liver disease (MAFLD) appear to be at higher risk for severe manifestations like acute respiratory distress syndrome, especially in the youngest decades. Our aim was to examine whether patients with imaging-defined MAFLD and/or with increased non-invasive liver fibrosis scores (FIB-4) are at higher risk for severe illness from COVID-19, using a machine learning model.